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Abstract
Background: The lipocalin family proteins, including lipocalin-2 and retinol-binding protein 4 (RBP4), are adipokines closely
associated with obesity-related metabolic disorders. In this study, we evaluated the association of serum lipocalin-2 and
RBP4 with intima-media thickness (IMT) and subclinical atherosclerosis in type 2 diabetic patients.
Methods and Results: Serum levels of lipocalin-2 and RBP4 were measured in 284 type 2 diabetic patients. Subclinical
atherosclerosis was assessed by IMT at carotid, femoral and iliac arteries with ultrasound. Patients with subclinical
atherosclerosis showed significantly higher circulating concentrations of lipocalin-2 and RBP4 when compared to those
without [112.9 (86.4 to 202.1) mg/L versus 77.2(55.0–150.4) mg/L, 37.1(32.3–40.8) mg/L versus 23.2(20.1–29.2) mg/L,
respectively; P= 0.002, P,0.001, respectively]. Moreover, positive correlations were observed between carotid IMT and
lipocalin-2 (r = 0.170, P= 0.018) or RBP4 (r = 0.132, P= 0.040), femoral IMT and lipocalin-2 (r = 0.160, P= 0.027), as well as
between iliac IMT and RBP4 (r = 0.241, P,0.001). Multiple logistic regression analysis further demonstrated that these two
adipokines were independent risk factors for subclinical atherosclerosis in type 2 diabetes.
Conclusion: Circulating levels of lipocalin-2 and RBP4 are positively correlated with carotid IMT and subclinical
atherosclerosis in type 2 diabetes, which suggests a potential role of these two lipid-binding chaperones in the
pathogenesis of vascular complications of diabetes.
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Introduction
Atherosclerotic disease is the primary cause of myocardial
infarction, stroke, and peripheral vascular disease, which remains
as the leading cause of death worldwide [1]. Identification of
atherosclerosis at the subclinical stages would essentially facilitate
earlier selection of more effective treatments which may lead to a
better prognosis. Currently, indexes including the intima-media
thickness (IMT), flow mediated vasodilatation (FMD) (markers of
endothelial dysfunction), arterial stiffness, and ankle-brachial index
(ABI) are most commonly used in routine clinical practice to
evaluate subclinical atherosclerosis [2]. Nevertheless, more con-
venient and reliable markers, such as serum biomarkers, for
subclinical atherosclerosis are yet to be identified.
Diabetes is one of the most important risk factors for
atherosclerosis [3]. In fact, 70% of the morbidity associated with
type 2 diabetes is related to atherosclerosis. In light of this, a better
understanding on the missing link between type 2 diabetes and
atherosclerosis would help to design more effective strategies for
early intervention of this disease.
Type 2 diabetes is commonly accompanied by the abnormal
production of adipokines [4]. Notably, a number of adipokines
have been implicated in vascular and atherothrombotic compli-
cations. The circulating levels of several pro-inflammatory
adipokines are elevated in pro-atherothrombotic and athero-
thrombotic states [5]. Lipocalin-2 (also known as 24p3, neutrophil
gelatinase-associated lipocalin and siderocalin) [6] and retinol
binding protein 4 (RPB4) [7] are novel adipokines that contribute
to insulin resistance and type 2 diabetes in obese rodents. Both of
them belong to the lipocalin family since they both share a
common tertiary structure known as the ‘lipocalin fold’ which
facilitates the binding of hydrophobic small molecules such as
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lipids [8]. Recent studies in human and animals have shown that
both lipocalin-2 [9,10,11] and RBP4 [7,12] are modulators of
insulin signaling and their levels are elevated in subjects with
obesity, insulin resistance, or type 2 diabetes. However, their
relevance to cardiovascular diseases is less investigated. A marked
elevation in lipocalin-2 expression was detected within atheroscle-
rotic plaques of atherosclerotic animal models [6]. Aigner F. et al.
demonstrated that lipocalin-2 regulates the inflammatory response
during ischemia and reperfusion of the transplanted heart [13]. In
the case of RBP4, two studies reported that circulating RBP4 levels
remarkably correlated with the degree of carotid IMT [14,15].
Plasma RBP4 concentrations were higher in those subjects with
previous clinical arteriosclerosis than in event-free subjects [16,17].
The above findings indicate a potential involvement of these
two lipocalin proteins in cardiovascular diseases. However, the
regulatory roles of circulating lipocalin-2 and RBP4 in type 2
diabetic patients with or without subclinical atherosclerosis have
not been reported yet. In this study, we assessed serum lipocalin-2
and RBP4 concentrations in patients with newly diagnosed type 2
diabetes in relation to subclinical atherosclerosis, as measured by
carotid, femoral and iliac arteries.
Methods
Ethics statement
This study was performed with the approval of the Institutional
Review Board (IRB) of the Second Xiangya Hospital, Central
South University. The written informed consent was received from
every subject.
Participants
Total 284 type 2 diabetic patients were enrolled in the Diabetes
Center at the Second Xiangya Hospital, Central South University
from the Chinese National Tenth Five Tackling Key Project
which was a multicenter study to evaluate the diabetic vasculo-
pathy in newly-diagnosed type 2 diabetes. Diabetes mellitus was
diagnosed according to the American Diabetes Association criteria
[18] with the following inclusion criteria: (1) disease duration less
than 1 year; (2) age from 35 to 70 years old; (3) body mass index
(BMI) from 19 to 35 kg/m2; (4) no ketosis within the first 6 months
after diagnosis; (5) no renal dysfunction; (6) 4-week wash out if
treated with insulin sensitizers; (7) no application of antihyperten-
sive drugs or lipid-lowering drugs within recent 2 months.
Hypertension was diagnosed when systolic blood pressure $
140 mm Hg and/or diastolic blood pressure $ 90 mm Hg or on
antihypertensive medication. Dyslipidemia was defined as having
one or more of the following criteria: (1) fasting triglycerides (TG)
$ 1.7 mmol/L; (2) HDL-cholesterol (HDL-C) , 1.30 mmol/L in
female and , 1.0 mmol/L in male; (3) LDL-cholesterol (LDL-C)
$ 3.4 mmol/L; and/or (4) already on lipid-lowering drug
according to United States Adult Treatment Panel III [19].
Smoking referred to both current and former smokers, whereas
nonsmoker referred to those who never smoked.
Clinical and biochemical assessments
A complete physical examination was performed on each
patient. Height was measured to the nearest 0.5 cm and weight to
the nearest 0.1 kg. Patients were measured in socks, stockings or
bare feet and light street clothing. BMI (body mass index) was
calculated as weight/height2 (kg/m2). Waist circumference was
measured midway between the lower rib margin and iliac crest.
Blood pressure measurements were taken on the right arm with
the subject seated for at least 10 min. Systolic and diastolic phase
blood pressures were recorded to the nearest 2 mmHg.
After overnight fasting, a venous blood specimen was collected
in the morning (around 8:00 am) for analysis of various
biochemical parameters as follows. FPG (fasting plasma glucose)
and 2hPG (2 h postprandial plasma glucose) were measured by
hexokinase method on a Hitachi 7170 analyzer (Boehringer
Mannheim, Mannheim, Germany). Serum cholesterol and TG
levels were determined enzymatically on the Hitachi 7170
analyzer (Boehringer Mannheim). Serum insulin was assessed by
chemiluminescence on a Bayer 180SE Automated Chemilumi-
nescence Systems (Bayer AG, Leverkusen, Germany). Insulin
resistance was estimated with the homeostasis model assessment
index (HOMA-IR), calculated as fasting glucose (in millimoles per
liter) times fasting insulin (in milliinternational units per liter)
divided by 22.5 [20]. Serum lipocalin-2 and RBP4 were measured
using ELISA kits with monoclonal antibodies established in our
laboratory (Antibody and Immunoassay Services, www.antibody.
hku.hk) as previously reported [11,21]. The intraassay and
interassay coefficients of variation for lipocalin-2 were 3.8%–
6.0% and 3.1%–5.2%, respectively. The intraassay and interassay
coefficients of variation for RBP4 were 4.1%–6.8% and 3.8%–
7.2%, respectively.
Vascular Ultrasound Measurement
Examinations for subclinical atherosclerosis were performed.
High-resolution B-mode ultrasound (128XP/10 system; Acuson,
Mountain View, California, USA) was used to measure the intima-
media thickness (IMT) of the target arteries (common carotid,
femoral and common iliac arteries on the right side). Linear
transducers with frequency of 10 to 12 MHz were used. An
anterolateral approach was used to longitudinally capture the right
common carotid, femoral and common iliac arteries. The best
image was selected to show the far wall intimal–lumen interface as
a continuous straight line. Three determinations of IMT were
made at 1 cm proximal to the bulb and at the site of greatest
thickness. The values at each site were averaged, and the averaged
IMT was used as the representative value for each individual.
Plaque was defined as IMT $1.3 mm or a focal protrusion into
the lumen with a thickness of at least 50% more than adjacent
intima-media complex. Subclinical atherosclerosis was defined as
IMT.1.0 mm and/or with plaque on one or more of the three
arteries (common carotid artery, femoral artery and common iliac
artery) but without clinical manifestations [22,23].
Statistical analysis
All statistical analyses were performed with Statistical Package
for Social Science Version 16.0 (SPSS 16.0, Inc., Chicago, IL).
Data were expressed as mean 6 SD or median with interquartile
range as appropriate. Data that were not normally distributed, as
determined using Kolmogorov-Smirnov test, were naturally
logarithmically transformed before analysis. Correlations between
lipocalin-2 or RBP4 and biochemical variables were analyzed with
Pearson correlation. Comparisons between groups were per-
formed using x2 tests for categorical variables and independent-
samples T test or univariate general linear model for continuous
variables as indicated. Multiple logistic regression analysis was
done to determine independent factors of subclinical atheroscle-
rosis, and included variables which were significantly different
between patients with and without subclinical atherosclerosis and
were biologically likely to be related with atherosclerotic status.
Two-sided P values ,0.05 were considered significant.
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Results
The anthropometric and biochemical characteristics of the type
2 diabetic patients are summarized in Table 1. Compared with
patients without subclinical atherosclerosis, patients with it had
significantly higher carotid IMT, femoral IMT, iliac IMT, systolic
blood pressure and elder age. Notably, serum lipocalin-2 and
RBP4 levels were significantly higher in patients with subclinical
atherosclerosis when compared to those in patients without [112.9
(86.4 to 202.1) mg/L versus 77.2(55.0–150.4) mg/L, 37.1(32.3–
40.8) mg/L versus 23.2(20.1–29.2) mg/L, respectively; P=0.002,
P,0.001, respectively].
Serum lipocalin-2 levels correlated positively with BMI, waist
circumference, TG and fasting insulin. Serum RBP4 levels
correlated positively with systolic blood pressure (Table 2). In
the whole study group, positive correlations were observed
between carotid IMT and lipocalin-2 (r = 0.170, P=0.018) or
RBP4 (r = 0.132, P=0.040), femoral IMT and lipocalin-2
(r = 0.160, P=0.027), as well as between iliac IMT and RBP4
(r = 0.241, P,0.001, Figure 1). In addition, serum lipocalin-2
correlated closely with RBP4 (r = 0.231, P=0.003).
Using a multiple logistic regression model, independent
significant risk factors for subclinical atherosclerosis were identi-
fied, including age, sex, BMI, smoking status, FPG, fasting insulin,
presence of hypertension, presence of dyslipidemia and lipocalin-2
or RBP4 (Table 3). Serum lipocalin-2 was independently
associated with subclinical atherosclerosis in type 2 diabetes (OR
2.10, 95% confidence interval (CI) 1.06–4.16, P=0.033), together
with age (P,0.001), BMI (P=0.001) and FPG (P=0.016).
Similarly, if lipocalin-2 was replaced by RBP4 in the model,
RBP4 was independently associated with subclinical atherosclero-
sis in type 2 diabetes (OR 1.16, 95% CI 1.10–1.22, P,0.001). If
FPG was replaced by 2hPG in both models, lipocalin-2 or RBP4
remained as a significant factor associated with subclinical
atherosclerosis in type 2 diabetes (OR 2.28, 95% CI 1.08–4.83,
P=0.031; OR 1.15, 95% CI 1.09–1.21, P,0.001, respectively).
When waist circumference replaced BMI in all models, the results
were similar (OR 2.29, 95% CI 1.17–4.49, P=0.016; OR 1.16,
95% CI 1.10–1.23, P,0.001, respectively). The significant
association between lipocalin-2 or RBP4 and subclinical athero-
sclerosis remained unchanged after the HOMA-IR was taken into
consideration when performing regression (OR 2.18, 95% CI
1.08–4.38, P=0.029; OR 1.17, 95% CI 1.11–1.24, P,0.001,
respectively).
Discussion
Atherosclerosis is a systemic disease affecting multiple territories
in the arterial wall. Subclinical atherosclerosis, as classified by 3
vessel beds involved (including carotid, femoral and iliac arteries),
is used to diagnose generalized atherosclerosis and considered as a
better predictor for cardiovascular events [22,23]. Our study
revealed an independent correlation between subclinical athero-
sclerosis and serum lipocalin-2 and RBP4 levels in type 2 diabetic
Table 1. Anthropometric and biochemical characteristics of type 2 diabetic subjects subdivided into subAS and non-subAS
subjects.
Parameters subAS(n=78) Non-subAS(n =206) P
Age (yr) 56.968.3 53.468.4 0.002
Sex (M/F) 38/40 106/100 NS
Smoking (%, Never-smoker/Former and current smoker) 61.2/38.8 62.6/37.4 NS
BMI (kg/m2) 25.162.8 24.562.8 NS
Waist circumference (cm)
Male 89.469.0 89.368.0 NS
Female 84.267.9 83.667.2
Systolic blood pressure (mmHg) 123617.6 118617.5 0.037
Diastolic blood pressure (mmHg) 75611.1 76610.3 NS
FPG (mmol/liter) 7.962.8 7.562.3 NS
2hPG (mmol/liter) 12.764.8 11.764.3 NS
TG (mmol/liter) { 1.6(1.1–2.3) 1.6(1.2–2.6) NS
LDL-C (mmol/liter) 3.261.1 3.060.9 NS
HDL-C (mmol/liter) 1.360.4 1.360.4 NS
Fasting insulin (mIU/liter) { 12.4 (8.2–18.3) 14.0 (9.0–19.0) NS
Carotid IMT (mm) 0.9460.34 0.7060.11 ,0.001
Femoral IMT (mm) 0.9760.33 0.7060.11 ,0.001
Iliac IMT (mm) 1.1360.28 0.7660.10 ,0.001
Lipocalin-2 (mg/liter) { 112.9(86.4–202.1) 77.2(55.0–150.4) 0.002
RBP4 (mg/liter) { 37.1(32.3–40.8) 23.2(20.1–29.2) ,0.001
Presence of hypertension (%) 26.9 22.3 NS
Presence of dyslipidemia (%) 72.7 69.9 NS
{Log transformed before analysis.
subAS, subclinical atherosclerosis; M, male; F, female; BMI, body mass index; FPG, fasting plasma glucose; 2hPG, 2 h postprandial glucose; TG, triglycerides; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IMT, intima-media thickness; RBP4, retinol-binding protein 4.
doi:10.1371/journal.pone.0066607.t001
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patients, suggesting that these lipocalins might be involved in the
early stage of diabetic vascular complications. Serum lipocalin-2
and RBP4 levels were significantly increased in patients suffering
from subclinical atherosclerosis. Serum lipocalin-2 levels correlat-
ed positively with individual components of subclinical athero-
sclerosis carotid IMT and femoral IMT, while serum RBP4 levels
positively correlated with carotid IMT and iliac IMT. Multiple
logistic regression analysis revealed that both serum lipocalin-2
and RBP4 were independent risk factors for subclinical athero-
sclerosis in type 2 diabetes, and the impact of lipocalin-2 or RBP4
on atherosclerosis was independent of age, sex, BMI, and other
classical cardiovascular risk factors.
The mechanisms by which these two lipocalin proteins mediate
the progression from type 2 diabetes to atherosclerosis are
unknown. We propose that they might serve as a relay between
inflammation and lipid metabolism in the transition from type 2
diabetes to atherosclerosis. It is now generally believed that
diabetes evokes inflammation, vasoconstriction and thrombosis
that collectively contribute to atherosclerosis [3]. In particular,
recent advances in basic science have established a fundamental
role of inflammation in almost every stage of atherosclerosis from
endothelial dysfunction to initiation, progression, and ultimately,
destabilization and rupture of plaques [24].
The pro-inflammatory features of lipocalin-2 and RBP4 have
been highlighted by several studies. Expression of lipocalin-2 is
induced in both acute and chronic inflammation [25]. The
lipocalin-2 promoter contains binding sites for a crucial pro-
inflammatory transcription factor, nuclear factor kB (NF-kB), and
lipocalin-2 was found to be highly induced in the intima following
angioplasty, as a consequence of NF-kb activation in a rat carotid
artery injury model [26,27]. More importantly, there are
evidences suggesting that lipocalin-2 may participate in the
development of atherosclerosis by inducing inflammation. Lipo-
calin-2 plays critical roles in regulating the expression of tumor
necrosis factor-a (TNF-a) in fat tissues, partly through upregulat-
ing 12-lipoxygenase expression and activity [28,29]. In both
atherosclerotic plaques and the intima of injured vessels, lipocalin-
2 colocalizes with matrix metalloproteinase 9 (MMP-9), a key
protease in inflammation and atherosclerosis [30]. Associations
between RBP4 and markers of inflammation have also been
implicated by a few clinical studies. Serum RBP4 levels were
increased and correlated with subclinical inflammation in child-
hood obesity [31], while in adipose tissue, mRNA level of RBP4
was positively linked to inflammatory markers rather than insulin
resistance [32]. Furthermore, high plasma RBP4 has been
associated with systemic inflammation in chronic kidney disease
in the absence of obesity and diabetes [33]. Taken together, it is
possible that lipocalin-2 and RBP4 mediate atherogenesis via
enhancing vascular inflammation in type 2 diabetes.
Hyperlipidemia is another risk factor for atherosclerosis.
Notably, lipocalins possess lipid-binding properties [34,35,36],
which may possibly mediate the hyperlipidemia evoked-inflam-
mation and atherosclerosis by acting as lipid sensors. It is
intriguing to investigate in the future whether the lipid binding
Figure 1. Correlations between lipocalins and IMTs. Correlations between serum Lipocalin-2 and (A) carotid IMT (n = 225) or (B) femoral IMT
(n = 223) in type 2 diabetic patients; correlations between serum RBP4 and (C) carotid IMT (n = 244) or (D) iliac IMT (n = 242) in type 2 diabetic patients.
Ln, natural logarithm.
doi:10.1371/journal.pone.0066607.g001
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capacity of these lipocalins is mandatory for their pro-inflamma-
tory and pro-atherogenesis activities. In light of this, lipocalin-2
and RBP4 might serve as critical links between lipid metabolism
and inflammation in atherogenesis.
Consistent with previous findings [9,11], we found that
circulating lipocalin-2 levels are related to BMI, waist circumfer-
ence, TG and fasting insulin. Nevertheless, circulating RBP4 levels
were exclusively related to systolic blood pressure. The relation-
ship between RBP4 and hypertension might be an underlying
cause in reinforcing the risk of atherogenesis [14]. We also
observed a close relationship between lipocalin-2 and RBP4.
However, their distinct correlations with various metabolic
parameters, suggest that lipocalin-2 and RBP4 should have
different patterns of regulation and there exists a complex
interconnection between these two lipocalin proteins and meta-
bolic disorders.
Our study has several limitations. Firstly, due to the relatively
small sample size and the cross-sectional design, the predictive
value of lipocalin-2 or RBP4 needs to be confirmed in a larger
cohort. Secondly, ultrasound can assess only the structural changes
in arteries, but not the vascular inflammatory status or qualitative
assessment. Therefore, fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) and virtual histology-IVUS may provide
more precise data on the vascular inflammation and plaque
components.
In conclusion, our study suggests that serum lipocalin-2 or
RBP4 levels reflect subclinical atherosclerosis in adults with newly
diagnosed type 2 diabetes. These findings support the roles of these
two lipid-binding chaperones in the pathogenesis of vascular
complications of diabetes, and provide possible perspective for
using lipocalin-2 and RBP4 as biomarkers for early detection of
high-risk individuals developing cardiovascular diseases and
potential therapeutic targets for atherosclerosis.
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